Buist A S, Sexton G J, Azzam A M, Adams B E
Am Rev Respir Dis. 1979 Oct;120(4):759-66. doi: 10.1164/arrd.1979.120.4.759.
In this paper we present the initial cross-sectional data from a prospective study of lung aging in heterozygotes for alpha 1-antitrypsin deficiency. Using a case-control design, our cases included 37 heterozygotes for alpha 1-antitrypsin deficiency, protease inhibitor phenotypes MZ and MS, selected because they were parents of children with homozygous alpha 1-antitrypsin deficiency identified in a statewide newborn screening program between 1971 and 1974. All of the heterozygotes were less than 40 yr of age. Our control subjects were selected from a random sample of a working population participating in a longitudinal study of lung aging, using a 2:1 match of control subjects to cases, matching age, sex, ethnic origin, and smoking. Using a respiratory symptom questionnaire, spirometry, and the single-breath N2 test, we found no significant difference between heterozygotes and control subjects in terms of respiratory symptoms or pulmonary function data. We conclude that to 40 yr of age, the heterozygous phenotype (Pi MZ and MS) is not a risk factor for impairment of pulmonary function.
在本文中，我们展示了一项针对α1-抗胰蛋白酶缺乏症杂合子肺老化的前瞻性研究的初始横断面数据。采用病例对照设计，我们的病例包括37名α1-抗胰蛋白酶缺乏症杂合子，蛋白酶抑制剂表型为MZ和MS，选择这些病例是因为他们是1971年至1974年间在全州新生儿筛查项目中被确诊为纯合子α1-抗胰蛋白酶缺乏症儿童的父母。所有杂合子年龄均小于40岁。我们的对照受试者是从参与肺老化纵向研究的工作人群随机样本中选取的，对照与病例的比例为2:1，匹配年龄、性别、种族和吸烟情况。通过呼吸症状问卷、肺活量测定和单次呼吸氮试验，我们发现杂合子与对照受试者在呼吸症状或肺功能数据方面无显著差异。我们得出结论，到40岁时，杂合子表型（Pi MZ和MS）不是肺功能受损的危险因素。
